Noetik CEO Ron Alfa (L) and CSO Jacob Rinaldi
August 28, 2024 07:00 AM EDTUpdated August 30, 02:51 AM
Financing
Startups
AI

Ex­clu­sive: Noetik rais­es $40M Se­ries A to ad­vance AI am­bi­tions in can­cer — with an un­like­ly lead in­vestor

Andrew Dunn

Senior Biopharma Correspondent

Af­ter serv­ing as Pfiz­er’s top lawyer and now chair­ing Al­ny­lam’s board, Amy Schul­man’s lat­est biotech bet could be seen as some­what of a sur­prise. …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

No­var­tis seeks more bolt-on deals as it pur­chas­es neu­ro start­up for up to $1.1B

Am­gen names Stan­ford ge­neti­cist and biotech founder to CSO post

NewAms­ter­dam aces Phase 3 tri­al, but in­vestors are skep­ti­cal

FDA up­dates la­bel of 33-year-old can­cer drug with new dose and warn­ing

Ky­owa Kirin ac­quires ex-US rights to Ku­ra’s leukemia treat­ment for $330M up­front

sponsored

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

A service from the Financial Times